Payment overview · 2025
General Payments
$104.88
6 reported records · 3 companies
Healthcare provider profile · identity verified
Charles Michael Littlejohn, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PRINCETON, KY · NPI 1831202738
Verified facts
What the public records show
CMS Open Payments records show Charles Michael Littlejohn, MD received $104.88 in general payments during 2025 across 6 reported records.
Axsome Therapeutics, Inc. accounted for 56.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.78 | 56.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.31 | 30.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.79 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.88 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.78 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 518 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 62 |
| Furosemide | Furosemide | 306 | 59 |
| Simvastatin | Simvastatin | 283 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 40 |
| Metformin Hcl | Metformin Hcl | 246 | 53 |
| Losartan Potassium | Losartan Potassium | 243 | 52 |
| Omeprazole | Omeprazole | 239 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 39 |
| Gabapentin | Gabapentin | 159 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 36 |
| Eliquis | Apixaban | 155 | 21 |
| Meloxicam | Meloxicam | 147 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 47 |
| Glimepiride | Glimepiride | 126 | 20 |
| Spironolactone | Spironolactone | 119 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 27 |
| Carvedilol | Carvedilol | 115 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 17 |
| Alprazolam | Alprazolam | 112 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 25 |
| Tramadol Hcl | Tramadol Hcl | 91 | 19 |
| Famotidine | Famotidine | 89 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 14 |
| Potassium Chloride | Potassium Chloride | 85 | 18 |
| Sertraline Hcl | Sertraline Hcl | 85 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 21 |
| Risperidone | Risperidone | 80 | 12 |
| Trazodone Hcl | Trazodone Hcl | 77 | 17 |
| Olanzapine | Olanzapine | 75 | suppressed |
| Azithromycin | Azithromycin | 69 | 57 |
| Meclizine Hcl | Meclizine Hcl | 69 | 16 |
| Trulicity | Dulaglutide | 65 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 64 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 14 |
| Prednisone | Prednisone | 64 | 46 |
| Buspirone Hcl | Buspirone Hcl | 63 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 15 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | suppressed |
| Methylprednisolone | Methylprednisolone | 59 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Nabumetone | Nabumetone | 54 | 20 |
| Lovastatin | Lovastatin | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Atenolol | Atenolol | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Haloperidol | Haloperidol | 44 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 30 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Indapamide | Indapamide | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Niacin Er | Niacin | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 20 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Clozapine | Clozapine | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 15 |
| Cilostazol | Cilostazol | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Humira(Cf) | Adalimumab | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Enulose | Lactulose | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Xolair | Omalizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.88 · 6 records | Axsome Therapeutics, Inc. | Auvelity, PADCEV, QULIPTA, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error